CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 300 enrolled
Drug / intervention
No interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04619147
NCT04619147N/ACompleted
CompareCT.gov

Invasive Fungal Infections in Patients Following Stem Cell Transplant

Peter MacCallum Cancer Centre, Australia·observational·Posted Nov 6, 2020·Updated Nov 14, 2024

In Brief

An observational study evaluating No intervention for Invasive Fungal Infections and Stem Cell Transplant Complications. Completed, enrolled 300 participants across 1 site.

Detailed Summary

This study will be a descriptive, retrospective evaluation and analysis of invasive fungal infections (IFI) conducted in patients who underwent allogeneic haematopoiectic stem cell transplant (aHSCT) in a single tertiary transplant centre, the Bone Marrow Transplant Clinical Service across Peter MacCallum Cancer Centre (PMCC) and Royal Melbourne Hospital (RMH), Victoria, Australia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Fungal Infections, Stem Cell Transplant Complications
CountriesAustralia
CollaboratorsMerck Sharp & Dohme LLC

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 6, 2020
Enrollment StartJan 15, 2022
Primary CompletionApr 20, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.7 years ago

Interventions

No interventionother

This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.